Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 1/2014

01.01.2014 | Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Bleeding Risk Prediction Models in Atrial Fibrillation

verfasst von: Isac C. Thomas, Matthew J. Sorrentino

Erschienen in: Current Cardiology Reports | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Novel, nonvitamin K antagonist oral anticoagulants (OACs) have demonstrated similar or superior efficacy to warfarin for ischemic stroke prevention in patients with atrial fibrillation (AF). As the prevalence of AF rises in a growing elderly population, these agents are becoming central to the routine practice of clinicians caring for these patients. Though the benefits are clear, the decision to treat the elderly patient with AF with long-term oral OACs is often a dilemma for the clinician mindful of the risk of major bleeding. Several bleeding risk prediction models have been created to help the clinician identify patients for whom the risk of bleeding is high, and would potentially outweigh the benefits of OAC therapy. In this review, we discuss the features of 8 bleeding risk prediction models, including the recently described HEMORR2HAGES, HAS-BLED, and ATRIA models, and approaches to assessing bleeding risk in clinical practice.
Literatur
1.
Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:546S–92.PubMedCrossRef
2.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.PubMedCrossRef
3.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.PubMedCrossRef
4.
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. Apixaban was superior to warfarin in preventing stroke and caused less bleeding.PubMedCrossRef
5.
Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534–9.PubMedCrossRef
6.
Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949–53.PubMedCrossRef
7.
Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368:1272–4.PubMedCrossRef
8.
Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011;106:997–1011.PubMedCrossRef
9.
DiMarco JP, Flaker G, Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149:650–6.PubMedCrossRef
10.
Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87:144–52.PubMedCrossRef
11.
Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91–9.PubMedCrossRef
12.
Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995;70:725–33.PubMedCrossRef
13.
14.
Aspinall SL, DeSanzo BE, Trilli LE, Good CB. Bleeding Risk Index in an anticoagulation clinic. Assessment by indication and implications for care. J Gen Intern Med. 2005;20:1008–13.PubMedCentralPubMedCrossRef
15.
Kuijer PMM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159:457–60.PubMedCrossRef
16.
Investigators TC. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337:657–62.CrossRef
17.
Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631–9.PubMedCrossRef
18.
Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713–9.PubMedCrossRef
19.
Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130:1390–6.PubMedCrossRef
20.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.PubMedCrossRef
21.
Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118:612–7.PubMedCrossRef
22.
Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58:395–401.PubMedCentralPubMedCrossRef
23.
Ruiz-Gimenez N, Suarez C, Gonzalez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:26–31.PubMed
24.
•• Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100. This study presents a novel bleeding risk score as a practicle tool to assess the bleeding risk of patients with atrial fibrillation.PubMedCrossRef
25.
Nieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J. 2008;29:1181–9.PubMedCrossRef
26.
Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC Member Countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422–34.PubMedCrossRef
27.
•• Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) Score. J Am Coll Cardiol. 2011;57:173–80. This study investigated predictors of bleeding in a cohort of anticoagulated patients and determined that the HAS-BLED score performed the best in predicting rates of major bleeding compared with other algorithms.PubMedCrossRef
28.
Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28:125–36.PubMedCrossRef
29.
•• Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared with warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012;60:861–7. Three bleeding risk scores were compared and the HAS-BLED score performed better than HEMORR(2)HAGES and ATRIA in predicting clinically relavant bleeding including intracranial hemorrhage.PubMedCrossRef
30.
Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomized, open-label, noninferiority trial. Lancet. 2008;371:315–21.PubMedCrossRef
31.
Lip GY, Banerjee A, Lagrenade I, Lane DA, Taillandier S, Fauchier L. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Circ Arrhythm Electrophysiol. 2012;5:941–8.PubMedCrossRef
32.
Tzoulaki I, Liberopoulos G, Ioannidis JP. Use of reclassification for assessment of improved prediction: an empirical evaluation. Int J Epidemiol. 2011;40:1094–105.PubMedCrossRef
33.
Pepe MS. Problems with risk reclassification methods for evaluating prediction models. Am J Epidemiol. 2011;173:1327–35.PubMedCrossRef
34.
Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004;35:2362–7.PubMedCrossRef
35.
Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians’ fears often unfounded. Arch Intern Med. 2003;163:1580–6.PubMedCrossRef
36.
Bradley BC, Perdue KS, Tisdel KA, Gilligan DM. Frequency of anticoagulation for atrial fibrillation and reasons for its nonuse at a veterans affairs medical center. Am J Cardiol. 2000;85:568–72.PubMedCrossRef
Metadaten
Titel
Bleeding Risk Prediction Models in Atrial Fibrillation
verfasst von
Isac C. Thomas
Matthew J. Sorrentino
Publikationsdatum
01.01.2014
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 1/2014
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-013-0432-9

Weitere Artikel der Ausgabe 1/2014

Current Cardiology Reports 1/2014 Zur Ausgabe

Interventional Cardiology (S Rao, Section Editor)

Percutaneous Mitral Valve Repair

Valvular Heart Disease (V Nkomo, Section Editor)

Paradoxical Low Flow Aortic Valve Stenosis: Incidence, Evaluation, and Clinical Significance

Nuclear Cardiology (V Dilsizian, Section Editor)

Artificial Intelligence in Medicine and Cardiac Imaging: Harnessing Big Data and Advanced Computing to Provide Personalized Medical Diagnosis and Treatment

Valvular Heart Disease (V Nkomo, Section Editor)

Incremental Value of 3-D Transesophageal Echocardiographic Imaging of the Mitral Valve

Valvular Heart Disease (V Nkomo, Section Editor)

Clinical Implications of Conduction Abnormalities and Arrhythmias After Transcatheter Aortic Valve Implantation

Nuclear Cardiology (V Dilsizian, Section Editor)

Impact of Obesity and Bariatric Surgery on Metabolism and Coronary Circulatory Function

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise